SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Clinical trial NCT02334865 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02334865
Sponsor: Roswell Park Cancer Institute
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Partial Response of Multiple Myeloma or Plasma Cell Leukemia Plasma Cell Myeloma

Start date: 2017-04-13
Primary completion: 2022-09-16
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.